Understanding surgical outcomes of perioperative durvalumab in AEGEAN study

Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.

Leave A Comment

Your email address will not be published. Required fields are marked *